샘플 요청 목록

 카트 문의
시장보고서
상품코드
1514170

세계의 HIV 치료제 시장

HIV Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 164 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

HIV 치료제 시장은 2030년까지 445억 달러에 도달할 것으로 예측됩니다.

2023년에 311억 달러로 평가된 HIV 치료제 시장은 2023-2030년 분석 기간에 복합 연간 성장률(CAGR) 5.3%로 성장하고 2030년에는 445억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 병용 HIV 치료제는 복합 연간 성장률(CAGR) 5.2%로 성장을 지속하고, 분석 기간 종료 시에는 290억 달러에 달할 것으로 예측됩니다. 인테그라제 억제제(INI) 부문의 성장률은 분석 기간 동안 복합 연간 성장률(CAGR) 5.8%로 추정됩니다.

미국 시장은 84억 달러를 나타낼 전망이며 중국은 복합 연간 성장률(CAGR) 8.8%로 성장할 것으로 예측됨

미국의 HIV 치료제 시장은 2023년 84억 달러로 평가되었습니다. 세계 2위 경제대국인 중국은 2030년까지 97억 달러 규모에 이를 것으로 예측되며, 예측 기간 동안 복합 연간 성장률(CAGR) 8.8%입니다. 다른 주목할만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 복합 연간 성장률(CAGR) 각각 2.7%와 4.3%로 예측되고 있습니다. 유럽에서는 독일이 복합 연간 성장률(CAGR) 3.4%로 성장할 것으로 예측됩니다.

HIV 치료제 - 주요 동향 및 촉진요인

HIV 치료제는 인간 면역결핍 바이러스(HIV)의 관리와 치료에 혁명을 가져왔고, 한때는 치명적인 진단이었던 것이 많은 사람들에게 관리 가능한 만성 질환으로 변화했습니다. 항레트로바이러스 요법(ART)의 개발은 환자가 낮은 바이러스 양을 유지하고 감염 위험을 줄이고 삶의 질을 향상시킬 수 있는 중요한 이정표였습니다. ART에서는 보통 뉴클레오시드계 역전사효소 억제제(NRTI), 비뉴클레오시드계 역전사효소 억제제(NNRTI), 프로테아제 억제제(PI), 인테그라제 사슬 전이 억제제(INSTI), 엔트리 억제제 등 약물 클래스의 약물을 조합하여 사용합니다. 이 다제 병용 요법은 바이러스가 내성을 얻는 것을 방지하는 데 효과적이며 효과적인 HIV 관리의 중요한 측면입니다. 지난 수십년동안, 더 나은 효능, 더 적은 부작용 및 단순화된 투약 요법에 의한 어드히어런스 개선을 제공하는 신약 제제의 개발에 큰 진보가 있었습니다.

HIV 치료제 시장에서 가장 주목할만한 동향 중 하나는 매일 경구 약물을 대체하는 편리하고 장기간 작용하는 주사 항 레트로 바이러스 약물의 개척입니다. 매월 또는 격월에 투여되는 이러한 주사제는 복용 어드히어런스를 개선하는 데 도움이 되며, 매일 정제 섭취와 관련된 스티그마를 감소시킵니다. 또한 개별 유전자 프로파일과 바이러스의 특성에 맞춘 치료로 치료 성적을 향상시키는 맞춤형 의료에 대한 주목도 높아지고 있습니다. 나노입자 기반 제형과 같은 약물 전달 시스템의 혁신도 HIV 치료제의 약동학과 생체 분포를 개선하기 위해 연구되었습니다. 또한 HIV 치료와 고위험 인구에 대한 사전 노출 예방제(PrEP) 및 종합적인 성 건강 서비스와 같은 다른 건강 관리 서비스와의 통합은 HIV 치료의 범위와 효능을 확대하고 있습니다.

HIV 치료제 시장의 성장은 의약품 개발의 기술적 진보, HIV 유병률 증가, 중저소득 국가에서 치료 접근의 확대 등 여러 요인에 의해 야기됩니다. 분자 생물학과 바이러스학의 진보는 새로운 치료 표적의 발견과 새로운 작용기전을 가진 약물의 개발을 촉진합니다. 특히 사하라 이남의 아프리카 및 기타 유병률이 높은 지역에서 HIV의 세계 부담 증가는 HIV 치료의 지속적인 기술 혁신과 접근성의 필요성을 강조합니다. 에이즈 구제를위한 대통령 긴급 계획(PEPFAR), 세계 에이즈, 결핵 및 말라리아 대책 기금과 같은 정부 이니셔티브 및 국제 프로그램은 자원이 제한된 환경에서 HIV 치료제의 가용성을 높이는 데 매우 중요합니다. 중요한 역할을 수행합니다. 또한 HIV 치료에 대한 인식과 수용 증가와 진단 능력의 향상이 치료의 보급을 뒷받침하고 있습니다. 제약업계의 연구개발에 대한 헌신과 전략적 파트너십과 제휴는 HIV 치료제 시장의 진전을 뒷받침하고 있으며, 환자가 최신의 가장 효과적인 치료에 접근할 수 있도록 합니다.

조사 대상 기업 예(전 52건)

  • AbbVie, Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Emcure Pharmaceuticals Pvt., Ltd.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • Hetero Drugs Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • ViiV Healthcare

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

BJH 24.07.25

Global HIV Drugs Market to Reach US$44.5 Billion by 2030

The global market for HIV Drugs estimated at US$31.1 Billion in the year 2023, is expected to reach US$44.5 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2023-2030. Combination HIV Medicines, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$29.0 Billion by the end of the analysis period. Growth in the Integrase Inhibitors (INIs) segment is estimated at 5.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$8.4 Billion While China is Forecast to Grow at 8.8% CAGR

The HIV Drugs market in the U.S. is estimated at US$8.4 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$9.7 Billion by the year 2030 trailing a CAGR of 8.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 4.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

HIV Drugs - Key Trends and Drivers

HIV drugs have revolutionized the management and treatment of Human Immunodeficiency Virus (HIV), transforming what was once a fatal diagnosis into a manageable chronic condition for many individuals. The development of antiretroviral therapy (ART) has been a significant milestone, enabling patients to maintain low viral loads, reduce transmission risks, and improve their quality of life. ART typically involves a combination of medications from different drug classes, including nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transfer inhibitors (INSTIs), and entry inhibitors. This multi-drug approach helps to prevent the virus from developing resistance, which is a critical aspect of effective HIV management. Over the past few decades, significant advancements have been made in developing new drug formulations that offer better efficacy, fewer side effects, and improved adherence through simplified dosing regimens.

One of the most notable trends in the HIV drugs market is the development of long-acting injectable antiretrovirals, which provide a convenient alternative to daily oral medications. These injectables, administered monthly or bi-monthly, help to improve adherence and reduce the stigma associated with daily pill intake. Additionally, there is a growing focus on personalized medicine, with treatments tailored to individual genetic profiles and viral characteristics, enhancing therapeutic outcomes. Innovations in drug delivery systems, such as nanoparticle-based formulations, are also being explored to improve the pharmacokinetics and biodistribution of HIV drugs. Furthermore, the integration of HIV treatment with other healthcare services, such as pre-exposure prophylaxis (PrEP) for high-risk populations and comprehensive sexual health services, is expanding the reach and effectiveness of HIV care.

The growth in the HIV drugs market is driven by several factors, including technological advancements in drug development, the increasing prevalence of HIV, and expanding access to treatment in low- and middle-income countries. Advances in molecular biology and virology have facilitated the discovery of new therapeutic targets and the development of drugs with novel mechanisms of action. The rising global burden of HIV, particularly in sub-Saharan Africa and other high-prevalence regions, underscores the need for continued innovation and accessibility in HIV treatment. Government initiatives and international programs, such as the President's Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis and Malaria, play a pivotal role in increasing the availability of HIV drugs in resource-limited settings. Additionally, the growing awareness and acceptance of HIV treatment, coupled with improved diagnostic capabilities, are driving higher treatment uptake. The pharmaceutical industry's commitment to research and development, along with strategic partnerships and collaborations, continues to fuel progress in the HIV drugs market, ensuring that patients have access to the latest and most effective treatments.

Select Competitors (Total 52 Featured) -

  • AbbVie, Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Emcure Pharmaceuticals Pvt., Ltd.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • Hetero Drugs Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • ViiV Healthcare

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • HIV Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Global Burden of HIV in High-Prevalence Regions Spurs Demand for Effective Treatments
    • Advances in Antiretroviral Therapy Propel Market Growth
    • Long-Acting Injectable Antiretrovirals Drive Adoption and Improve Adherence
    • Personalized Medicine Approaches Strengthen Business Case for Tailored HIV Treatments
    • Innovations in Drug Delivery Systems Generate Demand for Improved Formulations
    • Integration of HIV Treatment with Comprehensive Sexual Health Services Spurs Market Expansion
    • Government Initiatives and International Programs Enhance Market Accessibility
    • Growing Focus on PrEP (Pre-Exposure Prophylaxis) Expands Market Opportunities
    • Advances in Molecular Biology and Virology Propel Discovery of Novel Therapeutic Targets
    • Increased Availability of Generic HIV Drugs Generates Market Competition
    • Improved Diagnostic Capabilities Accelerate Demand for HIV Treatments
    • Rising Awareness and Acceptance of HIV Treatment Drive Adoption Rates
    • Enhanced Healthcare Infrastructure in Developing Regions Sustains Market Growth
    • Development of Combination Therapies Expands Market Potential
    • Addressing Drug Resistance Challenges Drives Continuous Innovation in HIV Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World HIV Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for HIV Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for HIV Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for HIV Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Combination HIV Medicines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Combination HIV Medicines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Combination HIV Medicines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Integrase Inhibitors (INIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Integrase Inhibitors (INIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Integrase Inhibitors (INIs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • JAPAN
    • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • CHINA
    • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: China 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • EUROPE
    • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for HIV Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for HIV Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for HIV Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • FRANCE
    • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: France Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: France 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • GERMANY
    • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: UK 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for HIV Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for HIV Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for HIV Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • INDIA
    • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: India Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: India 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: India Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: India 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for HIV Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for HIV Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for HIV Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for HIV Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for HIV Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for HIV Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • AFRICA
    • HIV Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for HIV Drugs by Drug Class - Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for HIV Drugs by Drug Class - Percentage Breakdown of Value Sales for Combination HIV Medicines, Integrase Inhibitors (INIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for HIV Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for HIV Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제